{"analyses":[{"ciLowerLimit":"0.622","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.184","groupDescription":"Cox model stratified by myeloma stage at enrollment, history of a bone marrow transplant, and number of prior treatment regimens, with a single treatment covariate.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3496","paramType":"Cox Proportional Hazard","paramValue":"0.858","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.56","spread":"1.56","upperLimit":"1.84","value":"1.7"},{"groupId":"OG001","lowerLimit":"1.75","spread":"1.75","upperLimit":"2.05","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"320"}],"units":"Participants"}],"description":"Overall survival was measured from the start of the treatment to death due to any cause. Overall Survival is represented as the number of deaths per 100-person- months and was computed by dividing the number of participants with an event of death that occurred during the study follow-up period by the total duration of follow-up (in 100 months) for all the participants in each cohort since participants had different lengths of follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"OG000","title":"Vorinostat + Bortezomib"},{"description":"Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"OG001","title":"Placebo + Bortezomib"}],"paramType":"NUMBER","populationDescription":"The analysis population includes all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization up to 32 months (final study analysis)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Events/100-person Months"}